Prevalence and factors associated with potential clinically significant drug-drug interactions in patients with cardiovascular diseases at hospital admission
References
- World Health Organization, Cardiovascular diseases (CVDs), July 2024; https://www.who.int/europe/news-room/fact-sheets/item/cardiovascular-diseases; last access date November 4, 2024.
- EUROSTAT, Population Structure and Ageing, February 2024; https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing; last access date July 25, 2024.
- M. E. Tinetti, T. R. Fried and C. M. Boyd, Designing health care for the most common chronic condition–multimorbidity, JAMA 307(23) (2012) 2493–2494; https://doi.org/10.1001/jama.2012.5265
- S. M. Dunlay and A. M. Chamberlain, Multimorbidity in older patients with cardiovascular disease, Curr. Cardiovasc. Risk Rep. 10 (2016) Article ID 3; https://doi.org/10.1007/s12170-016-0491-8
- V. J. Wirtz, W. A. Kaplan, G. F. Kwan and R. O. Laing, Access to medications for cardiovascular diseases in low- and middle-income countries, Circulation 133(21) (2016) 2076–2085; https://doi.org/10.1161/CIRCULATIONAHA.115.008722
- D. P. Chew, I. A. Scott, L. Cullen, J. K. French, T. G. Briffa, P. A. Tideman, S. Woodruffe, A. Kerr, M. Branagan and P. E. Aylward; NHFA/CSANZ ACS Guideline 2016 Executive Working Group: National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand, Australian clinical guidelines for the management of acute coronary syndromes, Heart Lung Circ. 25 (2016) 895–951; https://doi.org/10.1016/j.hlc.2016.06.789
- J. Tamargo, K. P. Kjeldsen, E. Delpón, A. G. Semb, E. Cerbai, D. Dobrev, G. Savarese, P. Sulzgruber, G. Rosano, C. Borghi, S. Wassmann, C. T. Torp-Pedersen, S. Agewall, H. Drexel, I. Baumgartner, B. Lewis, C. Ceconi, J. C. Kaski and A. Niessner, Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, Eur. Heart J. Cardiovasc. Pharmacother. .(4) (2022) 406–419; https://doi.org/10.1093/ehjcvp/pvac005
- G. Crescioli, A. Bettiol, R. Bonaiuti, M. Tuccori, M. Rossi, A. Capuano, S. Pagani, G. Spada, M. Venegoni, G. D. Vighi, G. Mannaioni, A. Vannacci and N. Lombardi, MEREAFaPS Study group, Risk of hospitalization associated with cardiovascular medications in the elderly italian population: A nationwide multicenter study in emergency departments, Front. Pharmacol. 11 (2021) Article ID 611102 (11 pages); https://doi.org/10.3389/fphar.2020.611102
- C. Paradissis, N. Cottrell, I. Coombes, I. Scott, W. Wang and M. Barras, Patient harm from cardiovascular medications, Ther. Adv. Drug. Saf. 12 (2021) 1–22; https://doi.org/10.1177/20420986211027451
- T. J. Oscanoa, F. Lizaraso and A. Carvajal, Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis, Eur. J. Clin. Pharmacol. 73(6) (2017) 759–770; https://doi.org/10.1007/s00228-017-2225-3
- World Health Organization, The third WHO global patient safety challenge: Medication without harm, 2019; https://www.who.int/patientsafety/medication-safety/en/; last access date July 29, 2024.
- National Institute for Health and Clinical Excellence (NICE), Medicines optimisation: The safe and effective use of medicines to enable the best possible outcomes, March 2015; https://www.nice.org.uk/guidance/ng5, last access date July 25, 2024.
- Pharmaceutical Society of Australia, Medicine safety to be the 10th National Health Priority area, 2019; https://www.psa.org.au/, last access date July 25, 2024.
- The Joint Commission, National Patient Safety Goals, https://www.jointcommission.org/standards/national-patient-safety-goals/, 2024; last access date July 20, 2024.
- Institute for Safe Medication Practices, Highalert medications in acute care settings, 2018; https://www.ismp.org/recommendations/high-alertmedications-acute-list; last access date July 20, 2024.
- F. Salvi, A. Marchetti, F. D’Angelo, M. Boemi, F. Lattanzio and A. Cherubini, Adverse drug events as a cause of hospitalization in older adults, Drug Saf. 35(1) (2012) 29–45; https://doi.org/10.1007/BF03319101
- C. Cahir, Curran C. Curran, C. Walsh, A. Hickey, R. Brannigan, C. Kirke, D. J. Williams and K. Bennett, Adverse drug reactions in an ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients, Front Pharmacol. 13 (2023) Article ID 1029067 (10 pages); https://doi.org/10.3389/fphar.2022.1029067
- J. G. Naples, J. T. Hanlon, K. E. Schmader and T. P. Semla, Recent literature on medication errors and adverse drug events in older adults, J. Am. Geriatr. Soc. 64(2) (2016) 401–408; https://doi.org/10.1111/jgs.13922
- M. Tissot, M. B. Valnet-Rabier, T. Stalder, S. Limat, S. Davani and V. Nerich, Epidemiology and economic burden of “serious” adverse drug reactions: Real-world evidence research based on pharmacovigilance dana, Therapie 77(3) (2022) 291–300; https://doi.org/10.1016/j.therap.2021.12.007
- K. Dalton and S. Byrne, Role of the pharmacist in reducing healthcare costs: current insights, Integr. Pharm. Res. Pract. . (2017) 37–46; https://doi.org/10.2147/IPRP.S108047
- M. Jermini, C. Fonzo-Christe, K. Blondon, C. Milaire, J. Stirnemann, P. Bonnabry and B. Guignard, Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis, Int. J. Clin. Pharm. 46(2) (2024) 496–505; https://doi.org/10.1007/s11096-023-01683-w
- L. Magro, E. Arzenton, R. Leone, M. G. Stano, M. Vezzaro, A. Rudolph, I. Castagna and U. Moretti, Identifying and characterizing serious adverse drug reactions associated with drug-drug interactions in a spontaneous reporting database, Front. Pharmacol. 11 (2021) Article ID 622862 (9 pages); https://doi.org/10.3389/fphar.2020.622862
- C. S. Moura, F. A. Acurcio and N. O. Belo, Drug-drug interactions associated with length of stay and cost of hospitalization, J. Pharm. Pharm. Sci. 12(3) (2009) 266–272; https://doi.org/10.18433/j35c7z
- J. P. Schmitt, A. Kirfel, M. T. Schmitz, H. Kohlhof, T. Weisbarth and M. Wittmann, The impact of drug interactions in patients with community-acquired pneumonia on hospital length of stay, Geriatrics (Basel) .(1) (2022) Article ID 11 (9 pages); https://doi.org/10.3390/geriatrics7010011
- L. Zerah, S. Henrard, I. Wilting, D. O’Mahony, N. Rodondi, O. Dalleur, K. Dalton, W. Knol, M. Haschke and A. Spinewine, Prevalence of drug-drug interactions in older people before and after hospital admission: analysis from the OPERAM trial, BMC Geriatr. 21(1) (2021) Article ID 571 (11 pages); https://doi.org/10.1186/s12877-021-02532-z
- T. Roblek, T. Vaupotic, A. Mrhar and M. Lainscak, Drug-drug interaction software in clinical practice: a systematic review, Eur. J. Clin. Pharmacol. 71(2) (2015) 131–142; https://doi.org/10.1007/s00228-014-1786-7
- R Core Team: A language and environment for statistical computing. R Foundation for Statistical Computing, 2018; https://www.R-project.org/; last access date 20 July 2024.
- B. Guthrie, B. Makubate, V. Hernandez-Santiago and T. Dreischulte, The rising tide of polypharmacy and drug–drug interactions: population database analysis 1995–2010, BMC Med. 13 (2015) Article ID 74 (10 pages); https://doi.org/10.1186/s12916-015-0322-7
- K. Barnett, S. W. Mercer, M. Norbury, G. Watt, S. Wyke and B. Guthrie, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, Lancet 380(9836) (2012) 37–43; https://doi.org/10.1016/S0140-6736(12)60240-2
- M. Petrovic, T. van der Cammen and G. Onder, Adverse drug reactions in older people: detection and prevention, Drugs Aging 29(6) (2012) 453–462; https://doi.org/10.2165/11631760-000000000-00000
- J. E. Hughes, V. Russo, C. Walsh, E. Menditto, K. Bennett and C. Cahir, Prevalence and factors associated with potential drug-drug interactions in older community-dwelling adults: A prospective cohort study, Drugs Aging 38(11) (2021) 1025–1037; https://doi.org/10.1007/s40266-021-00898-8
- L. A. Stevens, J. Coresh, T. Greene and A. S. Levey, Assessing kidney function – measured and estimated glomerular filtration rate, N. Engl. J. Med. 354(23) (2006) 2473–2483; https://doi.org/10.1056/NEJMra054415
- N. M. P. Maideen, Adverse effects associated with long-term use of proton pump inhibitors, Chonnam Med. J. 59(2) (2023) 115–127; https://doi.org/10.4068/cmj.2023.59.2.115
- Center for Drug Evaluation and Research, Clinical Drug Interaction Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry, January 2020; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cyto-chrome-p450-enzyme-and-transporter-mediated-drug-interactions; last access date July 10, 2024.
- US Food & Drug Administration, Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers, June 2023; https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers; last access date July 10, 2024.
- S. F. B. van der Horst, E. S. L. Martens, P. L. den Exter, M. H. A. Bos, T. E. van Mens, M. V. Huisman and F. A. Klok, Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes, Thromb. Res. 228 (2023) 21–32; https://doi.org/10.1016/j.thromres.2023.05.020
- S. J. Connolly, M. Sharma, A. T. Cohen, A. M. Demchuk, A. Członkowska, A. G. Lindgren, C. A. Molina, D. Bereczki, D. Toni, D. J. Seiffge, D. Tanne, E. C. Sandset, G. Tsivgoulis, H. Christensen, J. Beyer-Westendorf, J. M. Coutinho, M. Crowther, P. Verhamme, P. Amarenco, R. O. Roine, R. Mikulik, R. Lemmens, R. Veltkamp, S. Middeldorp, T. G. Robinson, T. J. Milling Jr, V. Tedim-Cruz, W. Lang, A. Himmelmann, P. Ladenvall, M. Knutsson, E. Ekholm, A. Law, A. Taylor, T. Karyakina, L. Xu, K. Tsiplova, S. Poli, B. Kallmünzer, C. Gumbinger and A. Shoamanesh; ANNEXA-I Investigators, Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage, N. Engl. J. Med. 390(19) (2024) 1745–1755; https://doi.org/10.1056/NEJMoa2313040
- M. Kovačević, S. Vezmar Kovačević, B. Miljković, S. Radovanović and P. Stevanović, The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study, Int. J. Clin. Pract. 71(10) (2017) Article ID e13005 (9 pages); https://doi.org/10.1111/ijcp.13005
- I. Marinović, V. Bačić Vrca, I. Samardžić, S. Marušić and I. Grgurević, Potentially inappropriate medications involved in drug-drug interactions at hospital discharge in Croatia, Int. J. Clin. Pharm. 43(3) (2021) 566–576; https://doi.org/10.1007/s11096-020-01164-4
- I. Samardžić, I. Marinović, N. Kuča and V. Bačić Vrca, Potential clinically significant drug-drug interactions in prescribed pharmacotherapy in an outpatient setting, Pharmazie 76(8) (2021) 390–395; https://doi.org/10.1691/ph.2021.1561
- T. Roblek, A. Deticek, B. Leskovar, S. Suskovic, M. Horvat, A. Belic, A. Mrhar and M. Lainscak, Clinical-pharmacist intervention reduces clinically relevant drug-drug interactions in patients with heart failure: A randomized, double-blind, controlled trial, Int. J. Cardiol. 203 (2016) 647–652; https://doi.org/10.1016/j.ijcard.2015.10.206
- A. Rivkin and H. Yin, Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients, J. Crit. Care 26(1) (2011) Article ID 104.e1-104.e1046 (6 pages); https://doi.org/10.1016/j.jcrc.2010.04.014
- S. Vik, P. Weidemann, I. E. M. Gangås, S. E. Knapstad and S. Haavik, Pharmaceutical interventions on prescriptions in Norwegian community and hospital pharmacies, Int. J. Clin. Pharm. 43(4) (2021) 872–877; https://doi.org/10.1007/s11096-020-01188-w
- I. A. Scott, S. N. Hilmer, E. Reeve, K. Potter, D. Le Couteur, D. Rigby, D. Gnjidic, C. B. Del Mar, E. E. Roughead, A. Page, J. Jansen and J. H. Martin, Reducing inappropriate polypharmacy: The process of deprescribing, JAMA Intern. Med. 175(5) (2015) 827–834; https://doi.org/10.1001/jamainternmed.2015.0324
- I. A. Scott, S. N. Hilmer and D. G. Le Couteur, Going beyond the guidelines in individualising the use of antihypertensive drugs in older patients, Drugs Aging 36(8) (2019) 675–685; https://doi.org/10.1007/s40266-019-00683-8
- E. Reeve, Deprescribing tools: A review of the types of tools available to aid deprescribing in clinical practice, J. Pharm. Pract. Res. 50 (2020) 98–107; https://doi.org/10.1002/jppr.1626
- E. Reeve, V. Jordan, W. Thompson, M. Sawan, A. Todd, T. M. Gammie, I. Hopper, S. N. Hilmer and D. Gnjidic, Withdrawal of antihypertensive drugs in older people, Cochrane Database Syst. Rev. .(6) (2020) Article ID CD012572 (61 pages); https://doi.org/10.1002/14651858.CD012572.pub2
- J. P. Sheppard, A. Benetos and R. J. McManus, Antihypertensive deprescribing in older adults: A practical guide, Curr. Hypertens. Rep. 24(11) (2022) 571–580; https://doi.org/10.1007/s11906-022-01215-3
Language: English
Page range: 693 - 708
Accepted on: Nov 18, 2024
Published on: Jan 9, 2025
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2025 Iva Marović, Mario Udovičić, Diana Rudan, Šime Manola, Ivana Samardžić, Vesna Bačić Vrca, Maja Ortner Hadžiabdić, Ivana Marinović, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.